Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Optimal treatment of rheumatoid arthritis: EULAR recommendations for clinical practice Bijlsma JWPol Arch Med Wewn 2010[Sep]; 120 (9): 347-53Three important concepts have become standard of care in treating rheumatoid arthritis (RA): 1) development of new drugs: biologic agents; 2) treatment strategies: not an individual drug, but the timely combination of different drugs, given as a specific strategy; 3) treat to target: targeting treatment to the individual patient and adapting treatment when necessary. These concepts led to the development of the European League against Rheumatism recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs. Three so called overarching principles have been formulated, followed by 15 concrete recommendations for the management of RA. These 15 recommendations are described and discussed in this review, with some personal comments. An enormous gain in the development of RA has been achieved, and it is now time to consolidate that gain and make optimal treatment available for every RA patient in Europe. The guidelines described in this article will help physicians to actually do so.|*Practice Guidelines as Topic[MESH]|Antirheumatic Agents/*therapeutic use[MESH]|Arthritis, Rheumatoid/*drug therapy/prevention & control[MESH]|Delivery of Health Care/*standards[MESH]|Drug Therapy, Combination[MESH]|European Union[MESH]|Evidence-Based Medicine[MESH]|Guideline Adherence/*standards[MESH]|Humans[MESH]|Methotrexate/*therapeutic use[MESH]|Poland[MESH]|Quality Assurance, Health Care/standards[MESH]|Rheumatology/*standards[MESH] |
